ArticleCureus2026
Topical Tacrolimus 0.1% in the Treatment of Thygeson's Superficial Punctate Keratitis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thygeson's superficial punctate keratitis (TSPK) is a rare and chronic eye condition characterized by recurrent flare-ups of symptoms such as photophobia and tearing. Various treatments have been attempted over the years, but none have been entirely successful in managing the condition. This report presents the case of a 21-year-old woman with bilateral TSPK who exhibited photophobia, tearing, and burning sensations. The patient was treated with an off-label non-ophthalmic topical tacrolimus 0.1% ointment, applied nightly into the inferior fornix and titrated with artificial tears to improve tolerance. Complete resolution of corneal lesions and symptoms was observed after three weeks, so the treatment was stopped. Although lesions reappeared following cessation of treatment, symptomatic relief persisted. This case highlights the potential of non-ophthalmic tacrolimus 0.1% ointment, a higher-concentration formulation not previously described in the TSPK literature, as an effective therapeutic option that may contribute to prolonged symptom control while avoiding the intraocular pressure risks associated with steroid use, particularly in young patients. Tacrolimus may represent a promising alternative therapy for patients requiring chronic management of TSPK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.